AUA releases analysis of data collected from 2021 annual census
Amanda North, MD, discusses the AUA census in depth, specifically highlighting the data collected on residents and fellows.
Association found between inherited gene variants and prostate cancer in Black men
The study found pathogenic or likely pathogenic variants in DNA damage repair genes and HOXB13 to be more frequently observed in Black men with a family history of cancer.
Investigational LG-IR-NMIBC treatment UGN-102 found to have long-term durability
The median DOR among the 15 patients in the study was 24.4 months (range, 10.1 to 30.7 months).
Rollover data from OLYMPUS trial show long-term durability of LG-UTUC treatment
"Jelmyto provides an effective and durable kidney-sparing treatment option and should be considered as primary therapy for adult patients with LG-UTUC,” said Phillip Pierorazio, MD.
Blue light cystoscopy as adjunct to white light found to decrease tumor recurrence in NMIBC
Risk of tumor recurrence in the BLC Registry group was significantly lower than in patients who received WLC alone.
Urologic group partnership to offer access to in-house PCR lab testing
The collaboration between Streamline Scientific and UroGPO will help deliver PCR technology to UroGPO members.
Concurrent/adjuvant ADT sequencing appears optimal in patients receiving prostate-only RT
“To our knowledge, this study represents the first time a significant association has been demonstrated between concurrent and adjuvant ADT sequencing and overall survival rates among prostate cancer patients," says Amar Kishan, MD.
Vibegron as crushed tablet found safe, efficacious in OAB
The pharmacokinetic drug GEMTESA, developed by Urovant Sciences, was given to adult patients as a single 75-mg dose in a phase 1 study.
Trial to evaluate shock wave therapy and PRP combination for erectile dysfunction
“I think a clinical trial like this that is funded by the NIH and taxpayer dollars will hopefully provide an unbiased answer of whether it works and who it works in,” says Ranjith Ramasamy, MD.
Antegrade administration of low-grade UTUC treatment found feasible
A retrospective multi-center trial assessed the safety and feasibility of antegrade administration of Jelmyto in patients with low-grade UTUC.
Trial enrollment for uUTI drug stopped early after primary outcome for efficacy was reached
The phase 3 EAGLE-2 and EAGLE-3 studies looked at outcomes for gepotidacin, an investigational agent for the treatment of uncomplicated urinary tract infection.
Combined ultrasound procedure found effective in treating ureteral stones
"These technologies have the potential to provide an advantageous and patient-centered solution for the gap between expectant management and urologic intervention for symptomatic ureteral stones,” says M. Kennedy Hall, MD, MHS.
Study finds inadequate patient education for scheduled urologic procedures
Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.
Modifier 22 incentive found to decrease opioid prescriptions following vasectomies
Using administrative claims data, investigators analyzed the opioid prescriptions filled for vasectomies before and after the expansion of Blue Cross Blue Shield of Michigan's modifier 22 program.
Kidney stone treatment is associated with financial toxicity
The team of investigators used the COST-FACIT tool to take into account both the time and money lost to treatment.
Experts warn that current prostate cancer messaging might actually be harmful
"If men were aware that just because they have no symptoms doesn’t necessarily mean they are cancer free, then more might take up offers for tests," says Vincent Gnanapragasam, MD.
New machine learning tool finds link between bladder cancer and tobacco smoking
“It doesn’t necessarily mean that you have cancer. But the more you smoke, the more mutations accumulate in your cells, and the more you increase your risk for developing cancer," said study author Marcos Díaz-Gay, PhD.
Biomarkers may be predictive of patient response to bladder cancer treatments
“Our work indicates that these genetic signatures may prove to be tremendously valuable in predicting immunotherapy response in patients with bladder cancer, but also other tumor types," says Dan Theodorescu, MD, PhD.
2 Clarke Drive Cranbury, NJ 08512